Plain-English translation of NCT07879885 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called , which is designed to treat moderate-to-severe plaque psoriasis by targeting a specific immune protein involved in the disease. The medication is an antibody—a type of protein that helps your immune system work in a more controlled way. The trial will check whether this treatment is safe and how well it works for people with significant psoriasis.
Doctors know that the immune system plays a key role in psoriasis, and blocking certain immune signals can help control the disease. This trial aims to learn whether this new medication can offer patients a safe and effective option for treating moderate-to-severe psoriasis.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic several times over 24 weeks total. After an initial 4-week screening period, you would receive three injections of the medication under your skin at weeks 0, 4, and 8. Then you would be monitored for an additional 12 weeks to see how your skin responds and to watch for any side effects. Throughout the study, the research team will check your psoriasis severity, ask about how you're feeling, and may run blood tests to ensure the treatment is working safely.
AI-generated summary from trial data · Nov 12, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Hansoh BioMedical R&D Company
Enrollment target
~390 participants
Started
July 2025
Primary completion
March 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.